Suchen
Legend Biotech Corp
LEGNZur Watchlist hinzufügen
19.145USD
+0.595+3.21%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
3.54BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Legend Biotech Corp Unternehmen
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Legend Biotech Corp Informationen
BörsenkürzelLEGN
Name des UnternehmensLegend Biotech Corp
IPO-datumJun 04, 2020
CEOHuang (Ying)
Anzahl der mitarbeiter2600
WertpapierartDepository Receipt
GeschäftsjahresendeJun 04
Addresse2101 Cottontail Lane
StadtSOMERSET
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl08873
Telefon17328505598
Websitehttps://investors.legendbiotech.com/
BörsenkürzelLEGN
IPO-datumJun 04, 2020
CEOHuang (Ying)
Führungskräfte von Legend Biotech Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
98.23K
-9.11%
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
12.90K
+40.88%
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Alan Bash
Mr. Alan Bash
President - CARVYKTI
President - CARVYKTI
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Director
Director
--
--
Mr. Carlos Santos
Mr. Carlos Santos
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Independent Director
Independent Director
--
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Mr. Wai Man (Philip) Yau, CPA
Mr. Wai Man (Philip) Yau, CPA
Independent Director
Independent Director
--
--
Dr. Fangliang (Frank) Zhang, Ph.D.
Dr. Fangliang (Frank) Zhang, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
98.23K
-9.11%
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
12.90K
+40.88%
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Alan Bash
Mr. Alan Bash
President - CARVYKTI
President - CARVYKTI
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Director
Director
--
--
Mr. Carlos Santos
Mr. Carlos Santos
Chief Financial Officer
Chief Financial Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Legend Biotech Corp?
Die fünf größten Anteilseigner von Legend Biotech Corp sind: Dr. Ying Huang, Ph.D.
Wie viele Institutionen halten Anteile an Legend Biotech Corp (LEGN)?
Mit Stand vom 2026Q1 halten 554 Institutionen Anteile an Legend Biotech Corp, mit einem Gesamtmarktwert von etwa 93.85M, was 50.74% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -15564003.00 gestiegen.